Phendimetrazine Tartrate Tablets
Overview of Phendimetrazine Tartrate Tablets
Dosage Strength
35 mg Tablet105 mg Extended-Release Capsule
General Information
Phendimetrazine is a nonamphetamine sympathomimetic amine that is taken orally. It is used as a short-term (8 to 12 weeks) anoretic adjuvant in the treatment of exogenous obesity. Phendimetrazine has similar pharmacologic effects to amphetamines. Phendimetrazine is only approved for usage as a single agent. The FDA authorized this medication in 1961.
Phendimetrazine tartrate is a weight loss drug that is chemically similar to amphetamines and is often used to treat obesity. Phendimetrazine tartrate, an appetite suppressant, is classified as a Schedule III substance by the Convention on Psychotropic Substances and the Uniform Controlled Substances Act of 1970.
When phendimetrazine tartrate was created in Germany in 1954, it was soon recognized for its efficacy and prospective benefits. By the 1960s, it had satisfied the FDA’s approval standards, passing its safety and effectiveness testing as an approved weight loss formula, and its popularity surged in the mid-1990s after the FDA banned the diet pill Ephedra for its hazardous and potentially fatal side effects.
According to the most recent diet pill rankings, phendimetrazine tartrate is the second most popular appetite suppressant compound in America, and when used as advised, it is regarded an effective and safe weight control assistance.
References
1.Phendimetrazine tartrate extended-release capsules package insert. Princeton, NJ: Sandoz Inc.; 2011 Oct.
2.Phendimetrazine tartrate extended-release capsules package insert. Laurelton, NY: Eon Labs Manufacturing, Inc.; 1994 Apr.
3.Elavil® (amitriptyline) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2000 Dec.
4.Aventyl® (nortriptyline) package insert. Indianapolis, IN: Eli Lilly and Company; 1998 Aug.
5.Vivactil® (protriptyline) package insert. East Hanover, NJ: Odyssey Pharmaceuticals, Inc.; 2003 Jan.
6.Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996;15:135—57.
7.Turtle, J.R. and Burgess, J.A. Hypoglycemic effect of fenfluramine in diabetes mellitus. Diabetes 1973; 22:858.
8.Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137—44.
9.Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000;17:662—4.
10.Enflurane package insert. Buffalo, NY: MINRAD Inc.; 2001 Jan.
11.Ultane® (sevoflurane) package insert. North Chicago, IL: Abbot Laboratories; 2003 Aug.
12.Halothane, USP package insert. North Chicago, IL: Abbott Laboratories; 1998 Mar.
13.Schifano F, Oyefeso A, Corkery J, et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol. 2003 Oct;18:519—24.
14.Unithroid™ (levothyroxine sodium tablets, USP) package insert. Bohemia, NY: Jerome Stevens Pharmaceuticals, Inc.; 2000 Aug.
15.Levothroid (levothyroxine sodium tablet) package insert. Shenandoah, IA: Lloyd Pharmaceutical; 2011 June.
16.Armour Thyroid® package insert. St. Louis, MO: Forest Pharmaceuticals Inc.; 2002 November.
17.Strattera® (atomoxetine) package insert. Indianapolis, IN: Eli Lilly and Company; 2008 May.
18.Wellbutrin XL® (bupropion) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006 June.
Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.